15.67

2.96% +0.45

Macrogenics Inc (MGNX)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$15.22

Aprire:

$15.64

Volume 24 ore:

610.62K

Capitalizzazione di mercato:

$980.32M

Reddito:

$56.91M

Utile/perdita netta:

$-9.06M

Rapporto P/E:

130.58

EPS:

0.12

Flusso di cassa netto:

$-79.97M

1 W Prestazione:

+7.62%

1M Prestazione:

+14.63%

6M Prestazione:

+195.10%

1 anno Prestazione:

+127.43%

Intervallo 1D:

$15.32

$16.14

Portata 52W:

$4.29

$21.88

Macrogenics Inc Stock (MGNX) Company Profile

Nome

Macrogenics Inc

Settore

Healthcare (1213)

Industria

Biotechnology (699)

Telefono

301-251-5172

Indirizzo

9704 Medical Center Drive, Rockville, MD

Dipendente

330

Cinguettio

@macrogenics

Prossima data di guadagno

2024-05-09

Ultimi documenti SEC

MGNX's Discussions on Twitter

Macrogenics Inc Stock (MGNX) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2023-12-20	Aggiornamento	Citigroup	Neutral → Buy
2023-11-07	Aggiornamento	Guggenheim	Neutral → Buy
2023-03-17	Downgrade	Guggenheim	Buy → Neutral
2022-11-22	Downgrade	Cowen	Outperform → Market Perform
2022-11-14	Aggiornamento	BMO Capital Markets	Market Perform → Outperform
2022-07-18	Downgrade	SMBC Nikko	Outperform → Neutral
2022-07-11	Downgrade	BMO Capital Markets	Outperform → Market Perform
2022-05-04	Downgrade	Guggenheim	Buy → Neutral
2022-02-28	Aggiornamento	Citigroup	Neutral → Buy
2022-02-11	Iniziato	BMO Capital Markets	Outperform
2022-02-04	Iniziato	SMBC Nikko	Outperform
2021-11-17	Ripresa	Guggenheim	Buy
2021-10-19	Iniziato	JMP Securities	Mkt Outperform
2021-10-15	Ripresa	BTIG Research	Buy
2021-04-26	Ripresa	Credit Suisse	Outperform
2021-03-12	Aggiornamento	Barclays	Underweight → Overweight
2020-12-22	Ripresa	H.C. Wainwright	Buy
2020-08-03	Downgrade	Citigroup	Buy → Neutral
2020-06-01	Aggiornamento	Guggenheim	Neutral → Buy
2020-05-26	Reiterato	H.C. Wainwright	Buy
2020-03-04	Iniziato	Barclays	Underweight
2019-12-19	Iniziato	Cantor Fitzgerald	Overweight
2019-12-18	Iniziato	Cantor Fitzgerald	Overweight
2019-11-21	Downgrade	Morgan Stanley	Equal-Weight → Underweight
2019-11-20	Ripresa	Guggenheim	Neutral
2019-05-03	Aggiornamento	Wedbush	Neutral → Outperform
2019-04-12	Iniziato	Guggenheim	Neutral
2019-02-07	Aggiornamento	Citigroup	Sell → Buy
2019-02-07	Downgrade	Wedbush	Outperform → Neutral
2019-02-06	Aggiornamento	Raymond James	Underperform → Mkt Perform
2019-02-04	Downgrade	Citigroup	Neutral → Sell
2018-12-10	Downgrade	Raymond James	Outperform → Underperform
2018-09-10	Ripresa	BTIG Research	Buy
2018-05-31	Iniziato	Evercore ISI	Outperform
2018-03-05	Iniziato	H.C. Wainwright	Buy
2017-03-31	Iniziato	Raymond James	Outperform

Mostra tutto

Macrogenics Inc Borsa (MGNX) Ultime notizie

MacroGenics Announces Date of First Quarter 2024 Financial Results Conference Call

GlobeNewswire Inc.

MacroGenics Analyst Impressed By Improved Safety Profile From Prostate Cancer Candidate

Benzinga

Why STAAR Surgical Shares Are Trading Higher By Around 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Benzinga

The Latest Analyst Ratings For Macrogenics

Benzinga

Simulations Plus Posts Upbeat, Joins Levi Strauss, BlackBerry And Other Big Stocks Moving Higher In Thursday's Pre-Market Session

Benzinga

MacroGenics Provides Phase 2 TAMARACK Study Early Interim Safety Data and Plans for Future Disclosures

GlobeNewswire Inc.

Macrogenics Inc Azioni (MGNX) Dati Finanziari

Macrogenics Inc (MGNX) Reddito 2024

MGNX ha riportato un ricavo (TTM) di $56.91 milioni per il trimestre terminato il 2023-12-31, un -61.96% declino anno su anno.

Macrogenics Inc (MGNX) Reddito netto 2024

MGNX l'utile netto (TTM) è stato di -$9.06 milioni per il trimestre terminato il 2023-12-31, un +92.44% aumento anno su anno.

Macrogenics Inc (MGNX) Flusso di cassa 2024

MGNX ha registrato un flusso di cassa disponibile (TTM) di -$79.97 milioni per il trimestre conclusosi con 2023-12-31, un +11.72% aumento anno su anno.